BR112018006633A2 - anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano - Google Patents

anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano

Info

Publication number
BR112018006633A2
BR112018006633A2 BR112018006633A BR112018006633A BR112018006633A2 BR 112018006633 A2 BR112018006633 A2 BR 112018006633A2 BR 112018006633 A BR112018006633 A BR 112018006633A BR 112018006633 A BR112018006633 A BR 112018006633A BR 112018006633 A2 BR112018006633 A2 BR 112018006633A2
Authority
BR
Brazil
Prior art keywords
antibodies
bind
cannabinoid receptor
human cannabinoid
receptor
Prior art date
Application number
BR112018006633A
Other languages
English (en)
Inventor
Kretz-Rommel Anke
Ferrini Roger
Original Assignee
Bird Rock Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bird Rock Bio Inc filed Critical Bird Rock Bio Inc
Publication of BR112018006633A2 publication Critical patent/BR112018006633A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pathology (AREA)

Abstract

a presente invenção está relacionada a novos anticorpos e fragmentos destes que se ligam ao receptor canabinóide 1 (cb1). os anticorpos e fragmentos destes como aqui revelados incluem anticorpos humanizados que se ligam ao receptor cb1. a invenção também inclui usos dos nticorpos para o tratamento de uma doença ou distúrbio responsivo ao antagonismo ou agonismo do receptor cb1.
BR112018006633A 2015-09-30 2016-09-27 anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano BR112018006633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235194P 2015-09-30 2015-09-30
PCT/US2016/053927 WO2017058771A1 (en) 2015-09-30 2016-09-27 Antibodies that bind human cannabinoid 1 (cb1) recetor

Publications (1)

Publication Number Publication Date
BR112018006633A2 true BR112018006633A2 (pt) 2018-10-23

Family

ID=58424250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006633A BR112018006633A2 (pt) 2015-09-30 2016-09-27 anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano

Country Status (20)

Country Link
US (2) US11421026B2 (pt)
EP (1) EP3356833A4 (pt)
JP (2) JP2019502651A (pt)
KR (1) KR20180117590A (pt)
CN (2) CN114805574A (pt)
AU (2) AU2016330471B2 (pt)
BR (1) BR112018006633A2 (pt)
CA (1) CA3000167A1 (pt)
CL (1) CL2018000824A1 (pt)
CO (1) CO2018004569A2 (pt)
EC (1) ECSP18031407A (pt)
HK (1) HK1256286A1 (pt)
IL (2) IL300015A (pt)
MA (1) MA43049A (pt)
MX (1) MX2018003982A (pt)
PE (1) PE20181199A1 (pt)
RU (1) RU2727018C1 (pt)
TW (1) TWI784932B (pt)
WO (1) WO2017058771A1 (pt)
ZA (1) ZA201802807B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
CA3066733A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
CN111557913B (zh) * 2020-07-07 2022-05-31 中国科学院空天信息创新研究院 靶向癫痫细胞的纳米光敏复合物及调控检测系统
WO2023234406A1 (ja) * 2022-06-03 2023-12-07 塩野義製薬株式会社 カンナビノイド１型受容体に結合する抗体
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
ES2304604T3 (es) * 2003-02-18 2008-10-16 Astrazeneca Ab Ensayos de cribado para moduladores de gpr55 de tipo cannabinoide-ligando.
CA2530087A1 (en) 2003-06-30 2005-02-03 Merck & Co., Inc. Radiolabeled cannabinoid-1 receptor modulators
US20050095674A1 (en) 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (en) * 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
CA2609783A1 (en) 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007039797A1 (en) * 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
WO2007058930A1 (en) * 2005-11-10 2007-05-24 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
UA99620C2 (en) 2007-05-23 2012-09-10 Мерк Шарп Энд Доме Корп. Pyridyl piperidine orexin receptor antagonists
US8293211B2 (en) * 2007-06-11 2012-10-23 Makscientific, Llc CB1 receptor antagonists and uses thereof
EP2500361B1 (en) 2008-05-09 2016-03-30 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
JP2014515361A (ja) * 2011-05-20 2014-06-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃｂ１受容体のアンタゴニスト
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
US9416103B2 (en) * 2012-01-09 2016-08-16 The Board Of Trustees Of The University Of Arkansas Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
US20150157580A1 (en) * 2012-05-25 2015-06-11 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP2698383B1 (en) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Detection of synthetic Cannabinoids
WO2014210205A1 (en) 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
JP2017500028A (ja) * 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｄｐｅｐ３抗体および使用方法
MX2016012403A (es) * 2014-03-27 2017-06-14 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor

Also Published As

Publication number Publication date
US11421026B2 (en) 2022-08-23
AU2016330471A1 (en) 2018-04-26
AU2022291658A1 (en) 2023-02-02
HK1256286A1 (zh) 2019-09-20
WO2017058771A1 (en) 2017-04-06
ECSP18031407A (es) 2018-05-31
IL300015A (en) 2023-03-01
JP7262522B2 (ja) 2023-04-21
RU2727018C1 (ru) 2020-07-17
JP2019502651A (ja) 2019-01-31
US20230159634A1 (en) 2023-05-25
CO2018004569A2 (es) 2018-11-22
MA43049A (fr) 2018-08-08
CN108513615B (zh) 2022-03-08
CN114805574A (zh) 2022-07-29
PE20181199A1 (es) 2018-07-23
US20180282406A1 (en) 2018-10-04
KR20180117590A (ko) 2018-10-29
IL258337A (en) 2018-05-31
EP3356833A1 (en) 2018-08-08
IL258337B2 (en) 2023-06-01
MX2018003982A (es) 2019-01-31
TWI784932B (zh) 2022-12-01
JP2021176849A (ja) 2021-11-11
CN108513615A (zh) 2018-09-07
EP3356833A4 (en) 2019-04-10
ZA201802807B (en) 2022-12-21
AU2016330471B2 (en) 2022-09-29
CA3000167A1 (en) 2017-04-06
CL2018000824A1 (es) 2019-04-12
WO2017058771A8 (en) 2018-04-19
TW201726733A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
BR112018006633A2 (pt) anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano
MX2016012403A (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
PH12017500890A1 (en) Antibody drug conjugates
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
BR112016022910A2 (pt) anticorpos contra her2 biespecíficos
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112015013127A2 (pt) imunoterapia com agentes de ligação
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201691541A1 (ru) Новые анти-baff антитела
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112014029219A8 (pt) moléculas de ligação de il-6
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
BR112018016383A2 (pt) método para tratar uma doença autoimune, e, anticorpo ou fragmento de ligação específico do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]